Physician profile
Daniel D Refoua
NPI 1598146383
$5,526.52
in general payments reported to CMS, 2019-2025
26 companies · $578 in 2025
The $578 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $483 · 2020: $790 · 2021: $1,740 · 2022: $685 · 2023: $747 · 2024: $504 · 2025: $578.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,829.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,829.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,024.00 | 2019-2023 | Xarelto |
| Amgen INC. | $920.09 | 2019-2025 | Otezla, Otezla, Repatha |
| Abbvie INC. | $865.31 | 2019-2025 | |
| Boston Scientific Corporation | $492.36 | 2020-2025 | Emblem Mri S-Icd, Accolade Sr, Resonate El Icd Vr |
| Nestle Healthcare Nutrition INC. | $447.37 | 2021-2022 | |
| Medtronic, INC. | $274.75 | 2023 | Linq II, Cobalt Dr Mri Surescan |
| Abbott Laboratories | $250.39 | 2021-2022 | |
| Lilly USA, LLC | $212.71 | 2020-2022 | |
| Novo Nordisk INC | $158.81 | 2022-2023 | |
| Optinose US, INC. | $125.00 | 2021 | |
| Vifor Pharma, INC. | $125.00 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $122.19 | 2024 | |
| Astrazeneca Pharmaceuticals Lp | $76.94 | 2021 | |
| Aimmune Therapeutics, INC. | $61.62 | 2023-2025 | Vowst |
| Abiomed | $53.96 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $47.69 | 2022-2023 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $43.95 | 2023 | Gattex |
| Pfizer INC. | $34.31 | 2020-2023 | |
| Bardy Diagnostics, INC. | $28.00 | 2021 | |
| Astellas Pharma US INC | $27.63 | 2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.15 | 2023 | Trulance |
| Vivus LLC | $24.10 | 2021 | |
| Mimedx Group, INC. | $23.77 | 2024 | |
| Genentech USA, INC. | $21.60 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.69 | 2021 | |
| Opko Pharmaceuticals, LLC | $20.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Refoua listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.